



## **Nkarta to Participate at Upcoming Investor Conferences**

November 4, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

**Cowen 5<sup>th</sup> Annual IO Next Summit**

November 15, 2021

11:15 a.m. ET - fireside chat presentation

**Stifel 2021 Virtual Healthcare Conference**

November 17, 2021

2:00 p.m. ET – fireside chat presentation

**Evercore ISI 4<sup>th</sup> Annual HealthCONx Conference**

December 1, 2021

4:20 p.m. ET – fireside chat presentation

A simultaneous webcast of the presentations will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately four weeks.

**About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

**Nkarta Media/Investor Contact:**

Greg Mann

Nkarta, Inc.

[gmann@nkartatx.com](mailto:gmann@nkartatx.com)